TrialAmerican journal of clinical dermatology2021

Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.

Lawrence F Eichenfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.